vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and INNOVATIVE INDUSTRIAL PROPERTIES INC (IIPR). Click either name above to swap in a different company.

INNOVATIVE INDUSTRIAL PROPERTIES INC is the larger business by last-quarter revenue ($66.7M vs $38.3M, roughly 1.7× ImmunityBio, Inc.). INNOVATIVE INDUSTRIAL PROPERTIES INC runs the higher net margin — 47.8% vs -161.8%, a 209.6% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -13.1%).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

Oxford Properties is a Canadian multinational corporation, with operations in real estate investment, development and property management. Its portfolio includes office, retail, industrial, multi-residential, life sciences and hotel assets. Established privately in 1960 and later wholly owned by the Ontario Municipal Employees Retirement System (OMERS) since 2003, the company is headquartered in Toronto with regional head offices in New York City, London, Australia, Singapore and Luxembourg. ...

IBRX vs IIPR — Head-to-Head

Bigger by revenue
IIPR
IIPR
1.7× larger
IIPR
$66.7M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+420.1% gap
IBRX
407.0%
-13.1%
IIPR
Higher net margin
IIPR
IIPR
209.6% more per $
IIPR
47.8%
-161.8%
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IBRX
IBRX
IIPR
IIPR
Revenue
$38.3M
$66.7M
Net Profit
$-61.9M
$31.8M
Gross Margin
99.0%
Operating Margin
-169.0%
47.8%
Net Margin
-161.8%
47.8%
Revenue YoY
407.0%
-13.1%
Net Profit YoY
-4.7%
-20.4%
EPS (diluted)
$-0.06
$1.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
IIPR
IIPR
Q4 25
$38.3M
$66.7M
Q3 25
$32.1M
$64.7M
Q2 25
$26.4M
$62.9M
Q1 25
$16.5M
$71.7M
Q4 24
$7.6M
$76.7M
Q3 24
$6.1M
$76.5M
Q2 24
$79.8M
Q1 24
$75.5M
Net Profit
IBRX
IBRX
IIPR
IIPR
Q4 25
$-61.9M
$31.8M
Q3 25
$-67.3M
$29.3M
Q2 25
$-92.6M
$26.0M
Q1 25
$-129.6M
$31.1M
Q4 24
$-59.2M
$40.0M
Q3 24
$-85.7M
$40.2M
Q2 24
$42.0M
Q1 24
$39.4M
Gross Margin
IBRX
IBRX
IIPR
IIPR
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
IBRX
IBRX
IIPR
IIPR
Q4 25
-169.0%
47.8%
Q3 25
-173.5%
45.5%
Q2 25
-269.8%
45.9%
Q1 25
-390.1%
47.4%
Q4 24
-919.0%
54.7%
Q3 24
-1314.3%
54.8%
Q2 24
53.1%
Q1 24
55.7%
Net Margin
IBRX
IBRX
IIPR
IIPR
Q4 25
-161.8%
47.8%
Q3 25
-209.8%
45.3%
Q2 25
-350.3%
41.4%
Q1 25
-784.9%
43.3%
Q4 24
-783.4%
52.2%
Q3 24
-1404.0%
52.6%
Q2 24
52.6%
Q1 24
52.3%
EPS (diluted)
IBRX
IBRX
IIPR
IIPR
Q4 25
$-0.06
$1.07
Q3 25
$-0.07
$0.97
Q2 25
$-0.10
$0.86
Q1 25
$-0.15
$1.03
Q4 24
$-0.08
$1.35
Q3 24
$-0.14
$1.37
Q2 24
$1.44
Q1 24
$1.36

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
IIPR
IIPR
Cash + ST InvestmentsLiquidity on hand
$242.8M
$47.6M
Total DebtLower is stronger
$393.7M
Stockholders' EquityBook value
$-500.5M
$1.8B
Total Assets
$501.9M
$2.4B
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
IIPR
IIPR
Q4 25
$242.8M
$47.6M
Q3 25
$257.8M
$41.9M
Q2 25
$153.7M
$104.9M
Q1 25
$61.6M
$133.3M
Q4 24
$149.8M
$151.2M
Q3 24
$130.4M
$172.4M
Q2 24
$160.9M
Q1 24
$173.5M
Total Debt
IBRX
IBRX
IIPR
IIPR
Q4 25
$393.7M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IBRX
IBRX
IIPR
IIPR
Q4 25
$-500.5M
$1.8B
Q3 25
$-524.3M
$1.9B
Q2 25
$-570.7M
$1.9B
Q1 25
$-591.4M
$1.9B
Q4 24
$-489.1M
$1.9B
Q3 24
$-745.1M
$1.9B
Q2 24
$1.9B
Q1 24
$2.0B
Total Assets
IBRX
IBRX
IIPR
IIPR
Q4 25
$501.9M
$2.4B
Q3 25
$519.0M
$2.3B
Q2 25
$402.1M
$2.3B
Q1 25
$303.8M
$2.4B
Q4 24
$382.9M
$2.4B
Q3 24
$364.6M
$2.4B
Q2 24
$2.4B
Q1 24
$2.4B
Debt / Equity
IBRX
IBRX
IIPR
IIPR
Q4 25
0.21×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
IIPR
IIPR
Operating Cash FlowLast quarter
$-70.4M
$198.2M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
6.22×
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
IIPR
IIPR
Q4 25
$-70.4M
$198.2M
Q3 25
$-68.9M
$45.6M
Q2 25
$-79.7M
$48.4M
Q1 25
$-85.9M
$54.2M
Q4 24
$-85.1M
$258.4M
Q3 24
$-98.8M
$64.9M
Q2 24
$64.2M
Q1 24
$71.6M
Free Cash Flow
IBRX
IBRX
IIPR
IIPR
Q4 25
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$-87.0M
Q4 24
$-87.3M
Q3 24
$-101.6M
Q2 24
Q1 24
FCF Margin
IBRX
IBRX
IIPR
IIPR
Q4 25
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
-526.9%
Q4 24
-1155.4%
Q3 24
-1663.2%
Q2 24
Q1 24
Capex Intensity
IBRX
IBRX
IIPR
IIPR
Q4 25
2.4%
Q3 25
2.3%
Q2 25
4.1%
Q1 25
6.8%
Q4 24
28.0%
Q3 24
45.7%
Q2 24
Q1 24
Cash Conversion
IBRX
IBRX
IIPR
IIPR
Q4 25
6.22×
Q3 25
1.56×
Q2 25
1.86×
Q1 25
1.75×
Q4 24
6.46×
Q3 24
1.61×
Q2 24
1.53×
Q1 24
1.82×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons